Wells Fargo
GMAB icon

Wells Fargo’s Genmab GMAB Stock Holding History

Wells Fargo’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.34M Sell
303,639
-15,953
-5% -$424K ﹤0.01% 2355
2026
Q1 		$8.57M Buy
319,592
+285,440
+836% +$8.55M ﹤0.01% 2162
2025
Q4 		$1.05M Buy
34,152
+26,527
+348% +$827K ﹤0.01% 3932
2025
Q3 		$234K Sell
7,625
-2,140
-22% -$52.1K ﹤0.01% 4852
2025
Q2 		$202K Buy
9,765
+289
+3% +$5.93K ﹤0.01% 4765
2025
Q1 		$186K Sell
9,476
-273,635
-97% -$5.74M ﹤0.01% 4764
2024
Q4 		$5.91M Sell
283,111
-417,293
-60% -$9.17M ﹤0.01% 2301
2024
Q3 		$17.1M Sell
700,404
-23,101
-3% -$618K ﹤0.01% 1416
2024
Q2 		$18.2M Sell
723,505
-22,972
-3% -$651K ﹤0.01% 1305
2024
Q1 		$22.3M Buy
746,477
+189,345
+34% +$5.56M 0.01% 1171
2023
Q4 		$17.7M Sell
557,132
-32,261
-5% -$1.01M ﹤0.01% 1262
2023
Q3 		$20.8M Sell
589,393
-46,988
-7% -$1.79M 0.01% 1065
2023
Q2 		$24.2M Sell
636,381
-16,876
-3% -$673K 0.01% 1018
2023
Q1 		$24.7M Buy
653,257
+17,429
+3% +$670K 0.01% 1003
2022
Q4 		$26.9M Sell
635,828
-35,718
-5% -$1.47M 0.01% 946
2022
Q3 		$21.6M Sell
671,546
-3,057
-0.5% -$107K 0.01% 1029
2022
Q2 		$21.9M Buy
674,603
+76,552
+13% +$2.48M 0.01% 1086
2022
Q1 		$21.6M Buy
598,051
+94,146
+19% +$3.23M 0.01% 1253
2021
Q4 		$19.9M Sell
503,905
-5,411
-1% -$226K 0.01% 1344
2021
Q3 		$22.3M Sell
509,316
-5,831
-1% -$262K ﹤0.01% 1573
2021
Q2 		$21M Sell
515,147
-147,246
-22% -$5.68M ﹤0.01% 1645
2021
Q1 		$21.7M Sell
662,393
-72,059
-10% -$2.71M ﹤0.01% 1613
2020
Q4 		$29.9M Buy
734,452
+45,953
+7% +$1.72M 0.01% 1282
2020
Q3 		$25.2M Buy
688,499
+34,088
+5% +$1.23M 0.01% 1268
2020
Q2 		$22.2M Sell
654,411
-286,239
-30% -$7.8M 0.01% 1306
2020
Q1 		$19.9M Buy
940,650
+4,034
+0.4% +$89.9K 0.01% 1236
2019
Q4 		$20.9M Sell
936,616
-4,453
-0.5% -$97.2K 0.01% 1433
2019
Q3 		$19.1M Buy
+941,069
New +$18.5M 0.01% 1470

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Wells Fargo's GMAB Position: Q2 2026 in Review

Wells Fargo reduced its Genmab (GMAB) stake by 5% in Q2 2026, selling an estimated $424K and leaving 303,639 shares worth $8.34M. The position accounts for ﹤0.01% of the portfolio, ranked #2355.

Wells Fargo first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $29.9M in Q4 2020. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Wells Fargo held 303,639 shares of Genmab worth $8.34M as of Q2 2026.
  • Wells Fargo sold 15,953 Genmab shares in Q2 2026, an estimated $424K.
  • Genmab made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2355 holding.
  • Wells Fargo first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Wells Fargo's Genmab position peaked at $29.9M in Q4 2020.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.